Tagged News

China Grants Conditional Approval to Seaweed-Derived Alzheimer's Drug Oligomannate

6 years ago

Chinese regulators have granted conditional approval to Oligomannate, a seaweed-derived drug for mild to moderate Alzheimer's disease, marking the first new Alzheimer's therapy approval in nearly two decades.
The drug, developed by Shanghai Green Valley Pharmaceuticals, showed cognitive improvements in a Phase 3 trial of 818 patients with benefits observed as early as four weeks.
Unlike traditional approaches targeting brain protein buildup, Oligomannate works by modulating the gut microbiome to reduce neuroinflammation associated with Alzheimer's disease.
The company plans to launch a global Phase 3 trial in 2020 with sites in the United States, Europe, and Asia to seek international regulatory approval.

7 years ago

The FDA has approved emapalumab-lzsg (Gamifant) as the first treatment specifically indicated for primary hemophagocytic lymphohistiocytosis (HLH), an ultra-rare and life-threatening immune disorder.
In a pivotal phase 2/3 study of 27 patients with refractory disease, 63% demonstrated overall response and 70% proceeded to hematopoietic stem cell transplant.
The monoclonal antibody targets interferon gamma, representing the first significant improvement in primary HLH induction therapy in 24 years.
Primary HLH typically affects children within the first year of life and has a median survival of less than two months without treatment.

NCT01818492CompletedPhase 2

Swedish Orphan Biovitrum

Posted 7/1/2013

8 years ago

Novartis's Kymriah, the first FDA-approved CAR-T cell therapy for pediatric acute lymphoblastic leukemia, demonstrates an impressive 83% remission rate in patients who failed traditional treatments.
The therapy's $475,000 price tag has ignited debate among healthcare experts, with some defending it as comparable to bone marrow transplants while others argue it's excessive despite its breakthrough status.
Novartis has implemented innovative value-based pricing models, including outcome-based contracts where payment is contingent upon patient response and indication-specific pricing for future approvals.

10 years ago

The FDA has approved Biocon's Yesintek (ustekinumab-kfce) and Celltrion's Steqeyma (ustekinumab-stba) in November and December 2024, expanding treatment options for autoimmune conditions including Crohn's disease and psoriasis.
Of the 65 FDA-approved biosimilars, 14 have received interchangeable designation, allowing pharmacists to substitute them for reference products without prescriber intervention, enhancing patient access to more affordable treatments.
The biosimilar landscape continues to evolve with products spanning five major classes: insulin, granulocyte colony-stimulating factors, monoclonal antibodies, TNF-alpha inhibitors, and VEGF inhibitors.

16 years ago

The FDA has approved Sanofi's Multaq (dronedarone) to reduce cardiovascular hospitalization risk in patients with atrial fibrillation or atrial flutter, representing the first new treatment option in this therapeutic area in twenty years.
The approval is based on five clinical studies involving 6,300 patients, with the landmark ATHENA trial demonstrating a 24% reduction in cardiovascular hospitalization or death from any cause compared to placebo.
Multaq showed significant clinical benefits including a 28% reduction in total hospital days and 35% decrease in heart-related hospitalization time in atrial fibrillation patients.
The drug is contraindicated in patients with severe heart failure, following results from the ANDROMEDA trial that showed increased mortality risk in this population.